EMA Authorised: Imraldi (adalimumab) — Samsung Bioepis NL B.V.

View source ↗

Summary

EMA authorised Imraldi, a biosimilar adalimumab by Samsung Bioepis NL B.V., for multiple inflammatory diseases including ankylosing spondylitis, rheumatoid arth…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ankylosing Spondylitis
• Crohn Disease
• Hidradenitis Suppurativa
• Psoriatic Arthritis
• Rheumatoid Arthritis
• Ulcerative Colitis
• Uveitis

Drugs mentioned

• Imraldi (adalimumab)

Snippet

Status: Authorised. Therapeutic area: Spondylitis, Ankylosing;Arthritis, Rheumatoid;Uveitis;Colitis, Ulcerative;Psoriasis;Arthritis, Psoriatic;Crohn Disease;Hidradenitis Suppurativa;Arthritis. MAH: Samsung Bioepis NL B.V.. Decision date: 15/01/2026